PEGylated insulin lispro compounds

Details for Australian Patent Application No. 2009257597 (hide)

Owner Eli Lilly and Company

Inventors Cutler, Gordon Butler; Doyle, Brandon; Shirani, Shahriar; Li, Shun; Zhang, Lianshan; Beals, John Michael; Hansen, Ryan John

Agent Spruson & Ferguson

Pub. Number AU-B-2009257597

PCT Pub. Number WO2009/152128

Priority 61/121,394 10.12.08 US; 61/061,281 13.06.08 US

Filing date 9 June 2009

Wipo publication date 17 December 2009

Acceptance publication date 6 October 2011

International Classifications

A61K 38/28 (2006.01) Medicinal preparations containing peptides - Insulins

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Event Publications

9 December 2010 PCT application entered the National Phase

  PCT publication WO2009/152128 Priority application(s): WO2009/152128

6 January 2011 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name Eli Lilly and Company, Application No. 2009257597, under INID (54) correct the title to read PEGylated insulin lispro compounds.

6 October 2011 Application Accepted

  Published as AU-B-2009257597

2 February 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009257601-Increasing capacity in wireless communications

2009257591-Implantable pump system